NYSE - Delayed Quote USD

Perrigo Company plc (PRGO)

Compare
27.13 -0.64 (-2.30%)
At close: September 20 at 4:00 PM EDT
27.16 +0.03 (+0.11%)
After hours: September 20 at 7:34 PM EDT
Loading Chart for PRGO
DELL
  • Previous Close 27.77
  • Open 27.70
  • Bid 26.90 x 1100
  • Ask 27.20 x 800
  • Day's Range 26.90 - 27.61
  • 52 Week Range 24.82 - 34.60
  • Volume 2,640,946
  • Avg. Volume 1,313,137
  • Market Cap (intraday) 3.701B
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) --
  • EPS (TTM) -0.83
  • Earnings Date Aug 2, 2024
  • Forward Dividend & Yield 1.10 (4.07%)
  • Ex-Dividend Date Aug 30, 2024
  • 1y Target Est 38.50

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

www.perrigo.com

9,140

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRGO

View More

Performance Overview: PRGO

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PRGO
13.17%
S&P 500
19.55%

1-Year Return

PRGO
15.93%
S&P 500
28.32%

3-Year Return

PRGO
31.91%
S&P 500
28.64%

5-Year Return

PRGO
42.78%
S&P 500
89.66%

Compare To: PRGO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRGO

View More

Valuation Measures

Annual
As of 9/19/2024
  • Market Cap

    3.79B

  • Enterprise Value

    7.31B

  • Trailing P/E

    2.75k

  • Forward P/E

    9.85

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.85

  • Price/Book (mrq)

    0.83

  • Enterprise Value/Revenue

    1.65

  • Enterprise Value/EBITDA

    23.90

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.81%

  • Return on Assets (ttm)

    1.20%

  • Return on Equity (ttm)

    -2.42%

  • Revenue (ttm)

    4.43B

  • Net Income Avi to Common (ttm)

    -113.8M

  • Diluted EPS (ttm)

    -0.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    542.8M

  • Total Debt/Equity (mrq)

    93.77%

  • Levered Free Cash Flow (ttm)

    173.89M

Research Analysis: PRGO

View More

Company Insights: PRGO

Research Reports: PRGO

View More

People Also Watch